The collaboration will also use Astellas’ universal donor cell and gene editing technology it obtained through its $102m acquisition of Universal Cells in 2018. Adaptimmune has already been ...

By combining Universal Cells' proprietary iPSC-derived cell ... armoring strategies for enhanced cell survival and persistence, and gene editing tools for immune cell engineering.

Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies. Read more to see why I rate FATE ...

A New Game Changer Decades in the Making Gene or genome editing is when a DNA sequence in a living cell is changed ... “It’s as if the bridge RNA were a universal power adapter that makes ...

Exagamglogene autotemcel (exa-cel) gene therapy offers a potential cure for severe sickle cell disease, now available on NHS.

“These p5 adapters label the naturally occurring breaks inside the cell at the time of the labeling process,” he added. “They may be breaks that are induced by your gene-editing system, but they can ...

Clinical trials for exa-cel have shown promising results that it has been authorised by the FDA and MHRA for use in beta thalassemia and sickle cell disease. These successes make CRISPR technology, as ...

Collaboration leverages Ginkgo's cell engineering and screening platform to enhance the potency and persistence of Universal Cells' iPSC-derived immune cell therapeutics ...

By combining Universal Cells' proprietary iPSC-derived cell technologies with ... armoring strategies for enhanced cell survival and persistence, and gene editing tools for immune cell engineering.